{"name":"Antengene Therapeutics Limited","slug":"antengene-therapeutics-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATG-037","genericName":"ATG-037","slug":"atg-037","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ATG-037","genericName":"ATG-037","slug":"atg-037","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQcHN5TlBNSVV6QTVUdU5neGt4bTJqQlAzRkF6UkI0TG13Z2lFZllIN0FmclpzU2ZJZ3YwM2o0TXd3VkxMUmV6N0I5cm43SEFYdkdPSGVKZHA3V0pibEZhWk8xUVhjaVlDcWYtZjJ5S21TZVN3VURPcUNDNnNiaWtQME9QOW9jeFY4bG5rbQ?oc=5","date":"2026-03-06","type":"pipeline","source":"pharmaphorum","summary":"Alnylam bets on Tenaya RNAi tech, and other licensing news - pharmaphorum","headline":"Alnylam bets on Tenaya RNAi tech, and other licensing news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE90bDZZXzhMOHFEWFdsZFVYZFVqLXQ2YzVfdEY5aGFRamlaZEVEUHk2LWxCOWc0OG9qQVJlSENIYXZJYWR1S2pqdVYzeThKRkRvTW1NZF9kQk5FYWl2LTcyamZnbUdfTVZQSkFYamxn0gFyQVVfeXFMUDhKa1B0TktQSkl0cnZpbkFZdmhnNkRXVnBzSHhUTUNNVk5FVDJma3l0TWVobkNuNWxuRjdwallMTHppb0lDbzZWQkZRbEgxeXFuSG9hZmZEUm1GZFYtR09QRUN0X3hpZmgzY2lOcVB5amRB?oc=5","date":"2026-03-04","type":"deal","source":"koreabiomed.com","summary":"Boryung adds Xpovio to blood cancer portfolio under Antengene license deal - koreabiomed.com","headline":"Boryung adds Xpovio to blood cancer portfolio under Antengene license deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNM1QxOV9KUG9ocjNrdmRUeENSYjBKOFJNNUlUd0dEdy1HdkRycm80dS00X3Q5SDdDMXlGMXZwMlJlaHBJOUhldFJJd2ZaYnNsazhUQnlpZVFJVTZYQkxxNU9pX2ZaZlQ3QklvQ1NBZXpYcHM0SE1qNW1OWnlKSlFLTDN0UXZWdlpIWDdTOVd4UQ?oc=5","date":"2026-03-04","type":"deal","source":"The Pharma Letter","summary":"UCB inks license agreement with Antengene - The Pharma Letter","headline":"UCB inks license agreement with Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPUFZXdG9JSzJjYjd6ZFIyeHJlMkVVQkp3VVRSalZ4YmNfdHNTSWRnX2tXclBhLWpFeUZJb3R4d2d1ZUdveTBqYkE2b2gxaGdtMEZOVGRyd29QN1VVblp2VHpMenQxdjdWdjI0Tjh1UWJpc29OYVlNRUJ3UlpqR0poTVJWbGZnZmFDUHRsUGhiUjZBZ2JTckxDV1ZPVUZpZGg3dEtBcnowa3Fzb211S3ZfeU43QWpTeFNpWWNVVg?oc=5","date":"2026-03-03","type":"deal","source":"Reuters","summary":"Belgium's UCB in autoimmune drug deal with Antengene - Reuters","headline":"Belgium's UCB in autoimmune drug deal with Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPNF9YNzZfNFdvblZJeV9YWWViZVBLY1pxZlZ6LVZUVktXaGtwaXluejduNnVZNFhLay1lZmlXWnV3THJMNVMxNGpQczZnNTNhVEJlSk05dGxNeDlJV0VVR2l3bkVtZkFvZE5RLWE5VEQwMFBSSm5oeVcxMVBlTnVEMXZHTHRsX3ZfQkdMVkZEMXNxUi1CMm00bm5feER1aHZPXzZOeVY4cXpIeVZWR3cxUWtMQUpOWmpjNWZCdDJaUHdmYm1ROFZCQkcyNDA2WlY0bGN1R2hnOGNNQndvNzJQQmFBV2Nqb0RjOWYzbm1IWlVQRXdtV1JRQ1FGSXhwTnZXX0xTbi1jNA?oc=5","date":"2026-03-03","type":"deal","source":"prnewswire.com","summary":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases - prnewswire.com","headline":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNYXpOdlA5SDJqZE5JVlNaWklrcEd1TThHVW82VGp5NUd3SUN0TU9ONUNFNFVOUENzenNHU1JCMmRja1BnaW9BOXNGdzg4S2ZGWWJMaDNZaGhFQ0pQOTRBM3IyVU9SVGtiWGxsOVNvVmhudGw5SDItdDNoVHFLOEd5V2ozSldvTzdscEJqYjZNRWFoYzdVTHNvSDNxOFZma1hmbnFuSGlGMjlsWWRBNjNCeVNwS2wzZ1FkbHhWMVhaNkU4ZkRaUmhrOWo0WUZwWVdOc0FxTGtkWmxRZ1VDV1pUV3BPUlpqM1FxMnQtNWVQdF9jYV9IOVdhc1U2XzUyR2FnYkFDQVIyZFJjV3d3Zk00SjFfV2t5Ul9xTmVDdzdSdEFJUm94aEdYemRRQW14Y3ExckV4UTA5R3pkaU9RbnJwZjM5eXdXTlhYRm5mSGhzMNIB1AJBVV95cUxQVl9mQjhsMkowQmdnaG5GaEZ2bFEyUDlxMVFCWTNzNHZVWGJkdmFxWkxNTzlmT2FZdTJmS0VlMEFmM3U1V2RINk1kNGFndk1mMFlCdHpYT0c3T1F2ZU5waWlObFpZOG9zME5JS2c0ZHcyNEdaRmEtYk9PUEJsbF85azUyd18wLVJ0cmFUUDZjQkVrY3JzLUl1a2dnQW5fRUZZV1FZOFFfQWpydTZZY2xJajRNbWxFZXFKb3N2dFN3Wkt5ZGt2TXNrVGdINWhwUkZWSmxkZWhqUHkxMVh5ZTRsdlVnQ0pOb1dLOFNvd1dTeDlfbmJBM21ZZ000dmlWRVQxdXU4WnlYX184TVZBdDNyN3RjX1Q3bHBkR1JKb1JIbDBqZ2pvNHJGV0hsQWFBWHAzSUNwUlMwZlk5dDgyZTdON3c3X0ZxODYyM1RSX1R3d3N6MWI0?oc=5","date":"2026-02-25","type":"deal","source":"The Manila Times","summary":"Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) - The Manila Times","headline":"Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQMjJfNjI2cEZBZTZtREl2bFdubkZOZnk0UzdUd0U0UTJ5Qnp6Q19vMVJaQlFzaWRTSjFGVG05YUhQYTR3a3ppRWRhLUc1bEotVkVkZXlnZ2V1cHVkS2ItUTF1UV9MbHRvUWU4Umt0UjVTM1RNUXctQ0pkOXNjWDk4UmNSVHVWRkZvbjB3ZkJETHFOb2g1cmtMcy1uRWlqaTFsNGduajRKMjF2WXc1OWlLRUhFUVFjNjM5cG5qV3JZVWdKVFRaWmlIMDR3SlBfLUJRV1B1WC1UMmdjR1g5MkFNeW1mTnlJanRjYmc4RHJ0dV9YSzZBbnB2emdkNHgtXzVyMnhWcENSSUc1MG5PRkN3OWw2T09pQURxSjZKLW5jOFJXbjBtSFdKbW0weTZscFdfekV4ZXBvdVFESnhibFNmb2FGalNCMW8wdTlIOW01TQ?oc=5","date":"2026-02-24","type":"deal","source":"prnewswire.com","summary":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) - prnewswire.com","headline":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNUzVnUUNqTVdBV0ZXaTg1eGx2b3FuZnZ3ZlR1VTFoMlM4OFF6aGdjLXBqaFJvRXBBN0N5ZXVUZzhpck11UExsWGI0WlJkWWVHQU1WN3U0WXpUclBrUHd5X3hXNGNBQlB6a0FBNnRmancydGpOTkVlcnRaV1VHNDVTTWUzUmx2eGhmTFF3TlMwM1kyZzRjemppcnZPZEdlN1puOVZRUjQ0bENjMUF6aDZSNVlLSkFlTXUtWFctTnljbkZ5ZDhPVHVtSXp5OA?oc=5","date":"2026-01-19","type":"trial","source":"BioPharma APAC","summary":"Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference - BioPharma APAC","headline":"Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPMzk1Q1NiYXRxNjBCUEEzY3NDRmU0ckJyakF3blRscU41cUdQSC11aTd4bmd3Q2tNTEs4eUVSRUhrSmMwSFVmcGtVazA5SHBSNXdfeXJfWUpMSTRYUFFfSXJ0eVk0NURnbjhVUzBFd3pIVG1VT3hqMWd6bG1wWC1pVWlXanNEMlZWT2k3WFJZMWZ0UzMzMFpVcHFKdmFoN3VFa3pnanhGbkdYQUFkdnFkazZqXzVnd04wdThVWVJCeFFQOTl2SUJXMFMyUGphYzVQOThHdEx6ZzhuM0ZPUHZwZWRZUFg3VTNETGRfYjY4Sm5sVHhQ?oc=5","date":"2026-01-15","type":"trial","source":"prnewswire.com","summary":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs - prnewswire.com","headline":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPQkItWjlCTkNrSnNRY2tJX2VRQUFTMFBENzFwdUd0U05kUzhaVFBLVThNdFJTYnRKeS1Yd3BROFVoemNTYm9PTmpNLWxjckRWVXduSFIxUmpfSzV3Y2dhREZwZWZkUHRtOWVtZVBNTEkzRDZicWpCZExSVFduaFRZZTRqNWVrbG5HZXAtWTZQR05YbG5wbE5XRFNSMHVZMkYyQXJGa3pzdC1LNzdBeWdIRDNycHVVY3pvS3JFclgyd0RfSkczZ0oteFI2QnNFb1BrRGlEaExMSXNVRkNFRlhQRDRxVzViVXN3dndHNzMyMFhoaHhJVDQyODhCYXppYlpvZEc1Z3FvUkt6LVFJWndOUV80b1I3aThzUkVaUDY3QWwxU1k?oc=5","date":"2025-08-19","type":"pipeline","source":"prnewswire.com","summary":"Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma - prnewswire.com","headline":"Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophagea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOTF9Hc18zTXFwanViT3BqYUNDTUlzVWtmSU4xVVpESExZWTQ4bldKZnNTQ2R0eWlGMTJ2cEs5TE1QZnFyNHR2MXBQdllRTXNrMnJMMlFkSlh2cG56R2R3WmNMaVMzRFFsYmpUeVZEVkQ5YUlIa1VmMzJMZFR4dVBYeEN1XzZYUkFOVlZvQWQyTUx2YzJZQnc0MVc0MnJDd3NYWl9NSQ?oc=5","date":"2025-05-21","type":"deal","source":"Contract Pharma","summary":"Antengene & MSD Enter into a Global Clinical Collaboration - Contract Pharma","headline":"Antengene & MSD Enter into a Global Clinical Collaboration","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}